R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
Fibrinogen gamma chain (E1U3Z) XP® Rabbit mAb #45850
Filter:
- WB
- IHC
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 50 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
IHC Leica Bond | 1:200 - 1:800 |
Immunohistochemistry (Paraffin) | 1:200 - 1:800 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
For a carrier free (BSA and azide free) version of this product see product #38915.
For a carrier free (BSA and azide free) version of this product see product #38915.
Protocol
Specificity / Sensitivity
Fibrinogen gamma chain (E1U3Z) XP® Rabbit mAb recognizes endogenous levels of total fibrinogen gamma chain protein. This antibody may cross-react with an unidentified protein of 70 kDa in some cell extracts.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser190 of human fibrinogen gamma chain protein.
Background
Fibrinogen is a large, multimeric plasma glycoprotein that is constitutively synthesized by liver hepatocytes. As a key component of blood clots, fibrinogen plays a central role in hemostasis and thrombosis. In total, six polypeptide chains (2Aα, 2Bβ, and 2γ) are produced intracellularly in a coordinated manner, which are then covalently linked together by a network of disulfide bonds to form a fibrinogen heterohexamer (1). Research studies have shown that expression of the three fibrinogen genes is upregulated as part of the acute phase inflammatory response (2,3).
Upon engagement of the clotting cascade, thrombin-mediated cleavage of the fibrinogen Aα and Bβ chains creates fibrin monomers and a platform for the polymerization of fibrin monomers into protofibrils and an insoluble web of stable fibrin fibers (4,5). Whereas thrombin is the enzyme that drives fibrin polymerization and clot formation, plasmin is the enzymatic counterpart that facilitates fibrinolysis and clot breakdown (6).
In addition to its position as a central node in the normal coagulation cascade, dysregulated fibrin deposition has been observed in pathological conditions such as cancer and viral infection (7,8).
The fibrinogen gamma chain is expressed as two isoforms that result from alternative mRNA splicing, the γA chain and the γ' chain. Research studies have shown that the fibrinogen gamma chain plays important roles in shaping the architecture of fibrin clots and modulates the innate immune response through interaction with its receptor, CD11b, expressed on neutrophils and monocytes (9,10).
Upon engagement of the clotting cascade, thrombin-mediated cleavage of the fibrinogen Aα and Bβ chains creates fibrin monomers and a platform for the polymerization of fibrin monomers into protofibrils and an insoluble web of stable fibrin fibers (4,5). Whereas thrombin is the enzyme that drives fibrin polymerization and clot formation, plasmin is the enzymatic counterpart that facilitates fibrinolysis and clot breakdown (6).
In addition to its position as a central node in the normal coagulation cascade, dysregulated fibrin deposition has been observed in pathological conditions such as cancer and viral infection (7,8).
The fibrinogen gamma chain is expressed as two isoforms that result from alternative mRNA splicing, the γA chain and the γ' chain. Research studies have shown that the fibrinogen gamma chain plays important roles in shaping the architecture of fibrin clots and modulates the innate immune response through interaction with its receptor, CD11b, expressed on neutrophils and monocytes (9,10).
- Chapin, J.C. and Hajjar, K.A. (2015) Blood Rev 29, 17-24.
- Dalmon, J. et al. (1993) Mol Cell Biol 13, 1183-93.
- Huber, P. et al. (1990) J Biol Chem 265, 5695-701.
- Lord, S.T. (2011) Arterioscler Thromb Vasc Biol 31, 494-9.
- Yang, Z. et al. (2000) Proc Natl Acad Sci U S A 97, 14156-61.
- Cesarman-Maus, G. and Hajjar, K.A. (2005) Br J Haematol 129, 307-21.
- Fernandez, P.M. et al. (2004) Semin Thromb Hemost 30, 31-44.
- Merad, M. and Martin, J.C. (2020) Nat Rev Immunol 20, 355-362.
- Yakovlev, S. et al. (2000) Biochemistry 39, 15721-9.
- Siebenlist, K.R. and Mosesson, M.W. (1994) J Biol Chem 269, 28414-9.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalStain is a registered trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.